. home.aspx

NEWS

home.aspx
   


Durham’s Mycovia Pharma extends clinical trial of anti-fungal drug for yeast infections

February 11, 2020 / Chantal Allam
SHARESHARESHARE

Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no approved treatment in the United States. “We are delighted by the progress we’re making with our oteseconazole clinical program, including the VIOLET trials,” said Stephen Brand, PhD, senior vice president of Clinical Development at Mycovia, in a statement. “The addition of an extension component to these studies will enable us to further evaluate the long-term effectiveness of oteseconazole in preventing recurrent episodes...